An Undervalued Stock to Buy and Hold for the Long Term

Why It Matters

At a steep discount with solid dividend income, FME presents a compelling long‑term play in the growing renal‑care market, despite near‑term headwinds.

Key Takeaways

• Trading 41% below EUR 67 fair‑value estimate.
• Dividend yield stands at 3.5% for income investors.
• High‑single‑digit earnings growth projected through 2030.
• Operating margin target mid‑teens, up from 11% 2025.
• Risks: policy changes, obesity drugs, technology disruption.

Pulse Analysis

Fresenius Medical Care remains the world’s largest dialysis provider, serving roughly 75% of the U.S. market and a growing share of emerging economies. Its scale gives it leverage over insurers and patients, while the aging global population and rising prevalence of diabetes and hypertension sustain demand for end‑stage renal disease treatment. The company’s at‑home dialysis solutions also tap a trend toward decentralized care, potentially expanding its addressable market and improving patient outcomes.

From a valuation perspective, FME’s shares are priced about 41% beneath Morningstar’s EUR 67 fair‑value target, translating into an attractive entry point for value‑oriented investors. The 3.5% dividend yield adds cash flow appeal, and ongoing share repurchases further enhance shareholder returns. Management’s roadmap to lift operating margins from 11% in 2025 to the mid‑teens aligns with projected low‑to‑mid‑single‑digit revenue growth, setting the stage for high‑single‑digit earnings compounding through 2030.

Nevertheless, the stock faces notable risks. U.S. policy shifts could pressure commercial‑insurance pricing, especially after the DaVita Supreme Court ruling, while the emergence of weight‑loss pharmaceuticals may curb the growth of the dialysis‑eligible population. Long‑term technological breakthroughs could eventually disrupt traditional dialysis models. Investors must weigh these uncertainties against the company’s moat of scale, geographic diversification, and steady cash generation when assessing the long‑term upside.